Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published July 19, 1994 | Published
Journal Article Open

Major Changes in the Expression of the mRNAs for Cholinergic Differentiation Factor/Leukemia Inhibitory Factor and its Receptor After Injury to Adult Peripheral Nerves and Ganglia

Abstract

The neuropoietic cytokine cholinergic differentiation factor/leukemia inhibitory factor (CDF/LIF) acts as a trophic factor, enhancing neuronal survival, and as a differentiation factor, altering neuronal gene expression. There is also evidence that it plays a role in the response of adult neural tissue to injury. We have examined this possibility further in rats by analyzing changes in the levels of mRNAs for CDF/LIF and its two receptor subunits in response to peripheral nerve damage in culture and in vivo. Using a quantitative RNase protection assay, we find that CDF/LIF mRNA increases dramatically (176-fold) in adult, but not neonatal, sympathetic ganglia and in adult dorsal root ganglia and sciatic nerve after organ culture for 24 hr. This mRNA is clearly detectable by in situ hybridization only in the nonneuronal cells of these structures. When the sciatic nerve is transected in vivo, CDF/LIF mRNA increases significantly in the regions immediately proximal and distal to the lesion site. The mRNA for the ligand binding subunit of the CDF/LIF receptor complex decreases somewhat upon culture and nerve section. The dramatic rise in CDF/LIF mRNA after nerve injury is further evidence that this cytokine is involved in the response to damage, a function that overlaps with its postulated role in wounding or infection in several nonneural tissues.

Additional Information

Copyright © 1994 by National Academy of Sciences Communicated by Seymour Benzer, April 22, 1994 We thank D. McDowell for help with tissue culture materials, K. Hatch for cloning of the GAPDH fragment, Drs. G. Kreutzberg and J. Gehrmann for the use of their MUC 102 antibody, and M.-J. Fann and M. Rao for constructive comments on the manuscript. This project was supported by grants from the Muscular Dystrophy Association (L.R.B.) and the National Institute of Neurological Disorders and Stroke (Javits Neuroscience Investigator Award) (P.H.P.). The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

Attached Files

Published - BANpnas94.pdf

Files

BANpnas94.pdf
Files (1.4 MB)
Name Size Download all
md5:e89d4cdda91810a92d9fb657da16ca6b
1.4 MB Preview Download

Additional details

Created:
August 22, 2023
Modified:
October 23, 2023